CMV IGG Antibodies in Semen as a Predictor for Blood Testis Barrier Damage
NCT ID: NCT05302856
Last Updated: 2022-08-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
30 participants
INTERVENTIONAL
2022-03-02
2023-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Correlation Analysis of Covid-19 IgG Antibody Level in Seminal Plasma and Semen Index
NCT05212506
Seminal Levels of PGK2 and ACRV1 as Predictors of Micro-TESE Results in NOA
NCT06307639
Spermatogonial Stem Cells in Azoospermic Patients: a Comparison Between Obstructive and Non-obstructive Azoospermia
NCT01178463
Home Semen Testing in Men Beginning Attempts to Conceive
NCT05503862
Semen Analysis Parameters Following Pfizer's COVID-19 Vaccine
NCT04778033
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study will evaluate semen and serum samples from the following groups:
1. Presumably fertile male patients going through ART treatment (for preimplantation genetic testing (PGT) or female indications).
2. Subfertile/infertile male patients with abnormal semen analysis.
3. Male patients suffering from unexplained infertility. All samples will be collected on the day of ovum retrieval procedure, and the semen samples will be evaluated only after completing the fertilization process. The samples will be tested for CMV IGG antibodies and testosterone levels in semen and serum. In addition, anti-sperm antibodies will be measured in the serum. The ratio between CMV IGG antibodies in semen and serum will be calculated, and will be compared with presence of hormone profile, semen analysis parameters and ART parameters.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Presumably fertile male patients going through ART treatment
Blood test (CMV IGG, Anti sperm antibody, Testosterone levels)
Peripheric blood extraction
Subfertile/infertile male patients with abnormal semen analysis
Blood test (CMV IGG, Anti sperm antibody, Testosterone levels)
Peripheric blood extraction
Male patients suffering from unexplained infertility
Blood test (CMV IGG, Anti sperm antibody, Testosterone levels)
Peripheric blood extraction
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood test (CMV IGG, Anti sperm antibody, Testosterone levels)
Peripheric blood extraction
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Male partner utilizing pre cycle frozen sperm sample
* Donor sperm cycles
* Surgically retrieved sperm
18 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hadassah Medical Organization
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chana Adler
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hadassah Medical Organization
Jerusalem, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Haverfield JT, Meachem SJ, Nicholls PK, Rainczuk KE, Simpson ER, Stanton PG. Differential permeability of the blood-testis barrier during reinitiation of spermatogenesis in adult male rats. Endocrinology. 2014 Mar;155(3):1131-44. doi: 10.1210/en.2013-1878. Epub 2013 Jan 1.
Stanton PG. Regulation of the blood-testis barrier. Semin Cell Dev Biol. 2016 Nov;59:166-173. doi: 10.1016/j.semcdb.2016.06.018. Epub 2016 Jun 25.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IGGSEMEN-HMO-CTIL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.